<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676893</url>
  </required_header>
  <id_info>
    <org_study_id>A99_02BE2002</org_study_id>
    <nct_id>NCT04676893</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, single dose, crossover study to evaluate the&#xD;
      pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of fifty-six (56), following treatments are administered dosing in each&#xD;
      period and wash-out period is a minimum of 14 days.&#xD;
&#xD;
      Reference drug: D418 Tab. / Test drug: CKD-388 Tab. Pharmacokinetic blood samples are&#xD;
      collected up to 72hrs. The pharmacokinetic characteristics and safety are assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 26, 2021</start_date>
  <completion_date type="Anticipated">May 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-388, D418</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.17, 0.33, 0.50, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
    <description>Area under the CKD-388/D418 concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-388, D418</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.17, 0.33, 0.50, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
    <description>The maximum CKD-388/D418 concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Reference-Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test-Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D418 Tab.</intervention_name>
    <description>1T</description>
    <arm_group_label>Reference-Test</arm_group_label>
    <arm_group_label>Test-Reference</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-388 Tab.</intervention_name>
    <description>1T</description>
    <arm_group_label>Reference-Test</arm_group_label>
    <arm_group_label>Test-Reference</arm_group_label>
    <other_name>Test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male volunteers, aged between ≥ 19 and ≤ 45 years old at the time of&#xD;
             screening.&#xD;
&#xD;
          2. Weight ≥ 50kg, with calculated body mass index (BMI) of ≥ 18.5 and ≤ 29.9 kg/m2&#xD;
&#xD;
             * BMI = Weight(kg)/ Height(m)2&#xD;
&#xD;
          3. Individuals who agreed proper contraception during the study and did consent to not&#xD;
             donation of sperm 1 month after the last dose of Investigational Product (IP)&#xD;
             administration&#xD;
&#xD;
          4. Individuals who voluntary decide to participate and agrees in writing to comply with&#xD;
             the precautions after hearing and fully understanding the detailed explanation of this&#xD;
             clinical tail&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of clinically significant and sever active cardiovascular,&#xD;
             respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrine, immune,&#xD;
             dermatologic, neurologic, or psychiatric disorder.&#xD;
&#xD;
          2. With symptoms indicating acute illness within 28 days prior to the first&#xD;
             Investigational Product (IP) administration.&#xD;
&#xD;
          3. Any medical history that may affect drug absorption, distribution, metabolism and&#xD;
             excretion.&#xD;
&#xD;
          4. Individuals who had history of hypersensitivity to follow drugs, derivative drugs or&#xD;
             others drugs(aspirin and antibiotics etc.) or had history of drug abuse&#xD;
&#xD;
               -  Thiazolidinedione&#xD;
&#xD;
               -  DPP-4 inhibitor&#xD;
&#xD;
               -  Metformin&#xD;
&#xD;
          5. Any clinically significant chronic medical illness.&#xD;
&#xD;
          6. Any genetic disease including galactose intolerance, Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
          7. Individuals with one of the following laboratory test results in screening&#xD;
&#xD;
               -  AST, ALT &gt; UNL (upper normal limit) x 3&#xD;
&#xD;
               -  Creatinine clearance ≤ 80 mL/min&#xD;
&#xD;
               -  In ECG result, QTc &gt; 450 msec&#xD;
&#xD;
               -  hCG(+) (only women)&#xD;
&#xD;
          8. Individuals who had positive test results at HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL.&#xD;
&#xD;
          9. Use of any prescription drugs within 14 days prior to study drug administration.&#xD;
&#xD;
         10. Use of over-the-counter medications and herbal preparations within 7 days prior to&#xD;
             study drug administration.&#xD;
&#xD;
         11. History of any clinically significant allergic reaction (However, mild allergic&#xD;
             rhinitis or allergic dermatitis which do not required medication may be allowed).&#xD;
&#xD;
         12. Individuals who cannot eat standard meal provided from clinical trial center.&#xD;
&#xD;
         13. Donation of blood within 60 days prior to study drug administration or apheresis&#xD;
             within 20 days prior to the first IP administration.&#xD;
&#xD;
         14. Individuals who had received a blood transfusion within 30 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
         15. Exposure to any investigational drug within 6 months prior to the first IP&#xD;
             administration.&#xD;
&#xD;
         16. Individuals taking any drugs inducing or inhibiting drug metabolizing enzymes&#xD;
             including barbiturates within 30 days prior to the first IP administration.&#xD;
&#xD;
         17. Individuals who had consumed grapefruit juice &gt; 5cups/day or caffeine &gt; 5cups/day&#xD;
             within 30 days prior to the first IP administration or who cannot stopping consume&#xD;
             grapefruit juice or caffeine during clinical study.&#xD;
&#xD;
         18. Individuals who had drinking (alcohol &gt; 30 g/day) within 30 days prior to the first IP&#xD;
             administration or who cannot stop drinking.&#xD;
&#xD;
         19. Heavy smoking (more than 10 cigarettes/day) within 30 days prior to screening or who&#xD;
             cannot quit smoking during clinical study.&#xD;
&#xD;
         20. Pregnant or women who may be pregnant&#xD;
&#xD;
         21. Subjects having been deemed inappropriate for the trial as determined by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji-Young Park, Professor</last_name>
    <phone>+82-2-920-6288</phone>
    <email>jypark21@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Ji-Young Park, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

